GlassScriptPhysician profile
Edelis Ocasio
NPI 1942746482
$4,460.85
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $986 · 2022: $1,883 · 2023: $1,451 · 2024: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,591.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,229.90 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $566.59 | 2021-2023 | |
| Amgen INC. | $230.96 | 2021-2024 | Otezla, Repatha |
| Lilly USA, LLC | $220.57 | 2021-2023 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $212.45 | 2021-2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.37 | 2021-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $159.45 | 2021-2023 | Belsomra, Verquvo, Steglatro |
| Astrazeneca Pharmaceuticals LP | $158.78 | 2021-2023 | Breztri |
| Glaxosmithkline, LLC. | $144.39 | 2021-2023 | Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $143.67 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $135.65 | 2022 | |
| Averitas Pharma INC. | $123.34 | 2023 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.17 | 2021-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $82.51 | 2021-2023 | |
| Astellas Pharma US INC | $72.37 | 2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edelis Ocasio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.